Hetero launches Favipiravir in India under the brand ‘Favivir’ to treat Covid-19

This is the second drug developed by Hetero after Covifor, the generic version of Remdesivir injection to be administered intravenously in a hospital for treatment of severe Covid-19, under the license from Gilead Sciences.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3hPh2xh
via IFTTT